| GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer C Pecoraro, B Faggion, B Balboni, D Carbone, GJ Peters, P Diana, ... Drug Resistance Updates 58, 100779, 2021 | 59 | 2021 |
| Chloride intracellular channel 1 activity is not required for glioblastoma development but its inhibition dictates glioma stem cell responsivity to novel biguanide derivatives F Barbieri, AG Bosio, A Pattarozzi, M Tonelli, A Bajetto, I Verduci, F Cianci, ... Journal of Experimental & Clinical Cancer Research 41 (1), 53, 2022 | 34 | 2022 |
| RX-3117 (fluorocyclopentenyl cytosine): A novel specific antimetabolite for selective cancer treatment B Balboni, B El Hassouni, RJ Honeywell, D Sarkisjan, E Giovannetti, ... Expert opinion on investigational drugs 28 (4), 311-322, 2019 | 20 | 2019 |
| ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders S Demuro, C Sauvey, SK Tripathi, RMC Di Martino, D Shi, JA Ortega, ... European journal of medicinal chemistry 229, 114054, 2022 | 17 | 2022 |
| Novel Insights into RAD52’s Structure, Function, and Druggability for Synthetic Lethality and Innovative Anticancer Therapies B Balboni, F Rinaldi, V Previtali, A Ciamarone, S Girotto, A Cavalli Cancers 15 (6), 1817, 2023 | 10 | 2023 |
| Identification of RAD51–BRCA2 Inhibitors Using N-Acylhydrazone-Based Dynamic Combinatorial Chemistry G Bagnolini, B Balboni, F Schipani, D Gioia, M Veronesi, F De Franco, ... ACS Medicinal Chemistry Letters 13 (8), 1262-1269, 2022 | 10 | 2022 |
| Innovative strategy toward mutant CFTR rescue in cystic fibrosis: design and synthesis of thiadiazole inhibitors of the E3 ligase RNF5 I Brusa, E Sondo, E Pesce, V Tomati, D Gioia, F Falchi, B Balboni, ... Journal of Medicinal Chemistry 66 (14), 9797-9822, 2023 | 8 | 2023 |
| GSK-3β allosteric inhibition: a dead end or a new pharmacological frontier? B Balboni, M Masi, W Rocchia, S Girotto, A Cavalli International Journal of Molecular Sciences 24 (8), 7541, 2023 | 7 | 2023 |
| Identification of Novel GSK-3β Hits Using Competitive Biophysical Assays B Balboni, SK Tripathi, M Veronesi, D Russo, I Penna, B Giabbai, ... International Journal of Molecular Sciences 23 (7), 3856, 2022 | 5 | 2022 |
| Isolation and characterization of monomeric human RAD51: a novel tool for investigating homologous recombination in cancer F Rinaldi, F Schipani, B Balboni, F Catalano, R Marotta, SH Myers, ... Angewandte Chemie 135 (51), e202312517, 2023 | 3 | 2023 |
| An integrative structural study of the human full-length RAD52 at 2.2 Å resolution B Balboni, R Marotta, F Rinaldi, G Milordini, G Varignani, S Girotto, ... Communications Biology 7 (1), 956, 2024 | 1 | 2024 |
| Novel structural insights on full-length human RAD52: Cryo-EM and beyond B Balboni, R Marotta, F Rinaldi, S Girotto, A Cavalli bioRxiv, 2023.04. 03.535362, 2023 | 1 | 2023 |
| METFORMIN, CLIC1 AND TRANSCRANIAL STIMULATION: THE BASIS OF A NEW TARGETED THERAPY AGAINST GLIOBLASTOMA RELAPSE G Cannavale Università degli Studi di Milano, 2023 | | 2023 |
| Metformin antiproliferative activity is exclusively mediated by the membrane functional expression of the Chloride Intracellular Channel 1 in glioblastoma stem cells I Verduci, F Cianci, R Cazzoli, G Cannavale, M Veronesi, B Balboni, ... bioRxiv, 2022.12. 31.522371, 2022 | | 2022 |
| Structural and biophysical characterization of RAD52 as novel pharmacological target for synthetic lethality B Balboni alma, 2022 | | 2022 |
